SecBot SecBot

EVFM

Evofem Biosciences, Inc.
OTC· Pharmaceutical Preparations· Inc. DE· CIK 0001618835 Biotech & Drug Discovery
$0.006500 −0.00 (−7.14%)
Oct 27 4:00 PM ET · prev $0.007000
Next earnings
Nov 11
in 15 days
1 year
−45.8%
from $0.0120 · Oct 28
30 days
−7.1%
from $0.007000
52-week range
$0.006000–0.0130
−50% from high · low May 5
Avg volume 20D
121.9K
Oct 14 spike 809.6K
Short interest
4.8K
−51.8%
Days to cover
1.0
at average volume
Filing reports
4
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Evofem Biosciences entered into a fifth amendment to its securities purchase agreement with Adjuvant…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • X Jul 31 Short interest falls 96.6% to 390
  • X Aug 14 Short interest jumps 7143.1% to 28.2K
  • X Sep 15 Short interest falls 61.9% to 11.2K
  • X Oct 15 Short interest falls 51.8% to 4.8K

Signal stack

Where each data set points today.

  • Short sellersCOVERING

    Short interest −51.8% to 4.8K shares. 1.0 days to cover.

  • TrendDOWNTREND

    13% below its 50-day average. New closing low $0.006000 on Oct 22.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
EVFM Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 12, 2026
Earnings date
EVFM Q2 2026 Earnings Scheduled — 2026-08-12
May 13, 2026
Earnings date
EVFM Q1 2026 Earnings Scheduled — 2026-05-13
Mar 23, 2026
Earnings date
EVFM Q4 2025 Earnings Scheduled — 2026-03-23

Earnings setup

Estimates
Nov 11
reports in 15 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
4,845
shares short
-51.8%
vs prior settlement
1.0
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Evofem Biosciences entered into a fifth amendment to its securities purchase agreement with Adjuvant, extending the…
8-K — Impact 3/10
Aug 12, 2026 Earnings calendar
EVFM Q2 2026 Earnings Scheduled — 2026-08-12
May 18, 2026 SEC
Evofem Biosciences reported Q1 2026 net sales of $0.9M (up from $0.8M YoY) but a net loss of $5.5M vs net income of…
8-K — Impact 4/10
Apr 30, 2026 SEC
Evofem entered into a 5-year exclusive distribution agreement with Clovis Davis Pharmaceuticals to commercialize…
8-K — Impact 4/10

SecBot reports

4 filings · 0 bullish · 0 bearish · 4 neutral
All EVFM filing & press-release reports (4)